Akers Biosciences (AKER) Reports Q3 GAAP Loss of $0.23/Share

Akers Biosciences (NASDAQ: AKER) reported Q3 EPS of ($0.23), versus ($0.30) reported last year. Revenue for the quarter came in at $453.3 million, versus $344.7 million reported last year.

The Street was looking for a Q3 loss of $0.17 per share (one estimate).

For earnings history and earnings-related data on Akers Biosciences (AKER) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance